Johnson & Johnson says it plans to file for approval of 11 new drugs by 2015 as it moves to expand its pharmaceutical business.
The New Brunswick, N.J., company is seeking approval for products including the prostate cancer drug abiraterone, blood thinner rivaroxaban, HIV drug TMC-278 and hepatitis C therapy telaprevir. Johnson & Johnson says it will also seek about 30 extensions on older product lines.
The company says it is trying to strengthen its business in Japan and plans to launch seven products there this year. Japan is the largest pharmaceutical market in the world after the U.S.
Johnson & Johnson is holding an investor meeting Thursday.